Brief: Harvard Apparatus Regenerative Technology to no longer provide hart-trachea product in Russia
26/11/2014 15:35
Nov 26 (Reuters) - Harvard Apparatus Regenerative Technology Inc HART.O : * Will no longer provide hart-trachea product for future transplant procedures performed in Russia * Continue to focus on completing preclinical work for clinical trials for hart-trachea product in EU, US * Expects to file investigational new drug application to initiate US clinical trial in 2015 for hart-trachea * Expects to file clinical trial authorization application for EU clinical trial in 2015 for hart-trachea * Source text for Eikon ID:nBw66vSPGa * Further company coverage HART.O ((Bangalore Newsroom; +1 646 223 8780))
Recent news on Harvard Apparatus Regenerative Technology
See all newsBrief: Harvard Apparatus Regenerative Technology Announces Strategic Collaboration With Children’S Hospital Capital Institute Of Pediatrics In Beijing, China To Advance Treatment For Esophageal Atresia
Brief: Biostage Activated Mayo Clinic As The First Site For Clinical Trial In Severe Esophageal Disease
Brief: Biostage Amends CEO Employment Agreement
Brief: Biostage Inc Files For Firm Commitment Public Offering Of 1.03 Million Units - SEC Filing
Brief: Biostage Announces Appointment Of New Chief Financial Officer